Iovance Bio Files 8-K on Operations and Financial Condition

Ticker: IOVA · Form: 8-K · Filed: Feb 20, 2024 · CIK: 1425205

Iovance Biotherapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyIovance Biotherapeutics, Inc. (IOVA)
Form Type8-K
Filed DateFeb 20, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.000041666, $346.3 million, $114.9 million, $165.0 million, $66.4 million
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, corporate-update, regulatory-filing

TL;DR

**Iovance Biotherapeutics just dropped an 8-K, likely signaling important updates on their business or financials.**

AI Summary

IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K on February 20, 2024, reporting an event that occurred on February 16, 2024. The filing indicates that the company, incorporated in Delaware with IRS Employer Identification No. 75-3254381, is providing an update on its operations and financial condition, as well as other events. This 8-K is filed under Commission File Number 001-36860.

Why It Matters

This filing signals that Iovance Biotherapeutics is providing an update on its business, which could include significant operational or financial developments impacting its future performance and investor sentiment.

Risk Assessment

Risk Level: medium — The filing mentions 'Results of Operations and Financial Condition' and 'Other Events' without specific details, which could indicate either positive or negative developments.

Key Numbers

  • 001-36860 — Commission File Number (SEC identification for the company's filings)
  • 75-3254381 — IRS Employer Identification No. (Tax identification for the company)
  • 2024-02-16 — Date of Report (earliest event) (Indicates when the reported event occurred)

Key Players & Entities

  • IOVANCE BIOTHERAPEUTICS, INC. (company) — Registrant
  • Delaware (company) — State of Incorporation
  • 75-3254381 (dollar_amount) — I.R.S. Employer Identification No.
  • 001-36860 (dollar_amount) — Commission File Number
  • February 16, 2024 (date) — Date of earliest event reported

FAQ

What is the purpose of this 8-K filing by IOVANCE BIOTHERAPEUTICS, INC.?

The 8-K filing by IOVANCE BIOTHERAPEUTICS, INC. is to report on 'Results of Operations and Financial Condition' and 'Other Events' as of February 16, 2024.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on February 16, 2024.

What is the Commission File Number for IOVANCE BIOTHERAPEUTICS, INC.?

The Commission File Number for IOVANCE BIOTHERAPEUTICS, INC. is 001-36860.

In which state is IOVANCE BIOTHERAPEUTICS, INC. incorporated?

IOVANCE BIOTHERAPEUTICS, INC. is incorporated in Delaware.

What is the IRS Employer Identification Number for IOVANCE BIOTHERAPEUTICS, INC.?

The IRS Employer Identification Number for IOVANCE BIOTHERAPEUTICS, INC. is 75-3254381.

Filing Stats: 608 words · 2 min read · ~2 pages · Grade level 9.6 · Accepted 2024-02-20 06:03:55

Key Financial Figures

  • $0.000041666 — h registered Common stock, par value $0.000041666 per value IOVA The Nasdaq Stock Marke
  • $346.3 million — 31, 2023, the Company had approximately $346.3 million in cash, cash equivalents, investments,
  • $114.9 million — ents, investments, and restricted cash ($114.9 million of cash and cash equivalents, $165.0 mi
  • $165.0 million — 9 million of cash and cash equivalents, $165.0 million in short-term investments, and $66.4 mi
  • $66.4 million — million in short-term investments, and $66.4 million in restricted cash). The foregoing inf

Filing Documents

02. Results of Operations

Item 2.02. Results of Operations and Financial Condition. Iovance Biotherapeutics, Inc. (the "Company") reports that as of December 31, 2023, the Company had approximately $346.3 million in cash, cash equivalents, investments, and restricted cash ($114.9 million of cash and cash equivalents, $165.0 million in short-term investments, and $66.4 million in restricted cash). The foregoing information reflects the Company's preliminary estimates with respect to cash, cash equivalents, investments, and restricted cash. This announcement is not a comprehensive statement of the Company's financial results and is subject to completion of an audit by the Company's independent registered public accounting firm. The Company's final financial results will be issued upon completion of such audit and may vary from these preliminary estimates.

01. Other Events

Item 8.01. Other Events. On February 16, 2024, the Company issued a press release announcing that AMTAGVI (lifileucel) has received U.S. Food and Drug Administration accelerated approval for the treatment of advanced melanoma. The Company also updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. A copy of the press release and the Company's corporate presentation are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated by reference herein. The information contained in Item 2.02 of this Current Report on Form 8-K is incorporated by reference herein.

01. Financial

Item 9.01. Financial (d) Exhibits. Exhibit Number Description 99.1 Press Release dated February 16, 2024 99.2 Iovance Biotherapeutics, Inc., Corporate Presentation - February 16, 2024 104 Cover Page Interactive Data File, formatted in Inline XBRL and included as Exhibit 101

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Iovance Biotherapeutics, Inc. Dated: February 20, 2024 By: /s/ Frederick G. Vogt Name: Frederick G. Vogt, Ph.D., J.D. Title: Interim CEO and General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.